Recent Progress in Polymeric Gene Delivery Systems

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 20, Issue 4, 2003, Pages 249-293

  Anwer, Khursheed ^a   Rhee, B G ^a   Mendiratta, Sanjeev Kumar ^a  

^a Expression Genetics Inc   (United States)

Author keywords

Functionalized polymers; Gene therapy; Nonviral gene delivery

Indexed keywords

CHITOSAN; COMPLEMENTARY DNA; CYTOKINE; DENDRIMER; DEXTRAN; DNA; INTERLEUKIN 12; LIPOPOLYMER; MACROGOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; N (2,3 DIOLEOYLOXY)PROPYL N,N,N TRIMETHYLAMMONIUM CHLORIDE; POLY N (2 HYDROXYPROPYL)METHACRYLAMIDE; POLY(2 DIMETHYLAMINO)ETHYL METHACRYLATE; POLY(4 HYDROXYPROLINE) ESTER; POLY(ETHYL ACRYLIC ACID); POLY(PROPYL ACRYLIC ACID); POLY(TRIMETHYLAMMONIO)ETHYL METHACRYLATE CHLORIDE; POLY[ALPHA (4 AMINOBUTYL)GLYCOLIC ACID]; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; POLYMETHACRYLIC ACID; POLYPHOSPHOESTERASE; POLYPROPYLENEIMINE; POVIDONE; RECOMBINANT PROTEIN; THROMBOSPONDIN 2; TRANSFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE TOXICITY; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL TRANSPORT; CLINICAL TRIAL; COMPLEX FORMATION; CYTOTOXICITY; DIABETES MELLITUS; DRUG COST; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; KIDNEY CARCINOMA; NONHUMAN; REVIEW; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; VALIDATION PROCESS;

ANIMALS; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; POLYMERS; VACCINES, SYNTHETIC;

EID: 0242349735     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i4.10     Document Type: Review

References (225)

1. Rolland AP. From genes to gene medicines: recent advances in nonviral gene delivery. Crit Rev Ther Drug Carrier Syst 1998; 15:143-198.
2. Zuckerbraun BS, Tzeng E. Vascular gene therapy: a reality of the 21st century. Arch Surg 2002; 137:854-861.
3. Rolland A, Tomlinson E. Controllable gene therapy using non-viral systems. In: Felgner P, Heller M, Lehn P, Behr JP, Szoka FC, editors. Artificial self-assembling systems gene delivery. Washington DC, ACS Books, 1996.
4. Rubanyi GM. The future of human gene therapy. Mol Aspects Med 2002; 22: 113-122.
5. Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applications and future goals. Stem Cells 1999; 17:191-202.
6. Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr Gene Ther 2002; 2:183-194.
7. Tan Y, Huang L. Overcoming the inflammatory toxicity of cationic gene vectors. J Drug Target 2002; 10:153-160.
8. Phillips AJ. The challenge of gene therapy and DNA delivery. J Pharm Pharmacol 2001; 53:1169-1174.
9. Saint George JA. Gene therapy progress and prospects:adenoviral vectors. Gene Ther 2003; 10:1135-1141.
10. Davis ME. Non-viral gene delivery systems. Curr Opin Biotechnol 2002; 13:128-131.
11. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 9:1647-1652.
12. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18: 33-37.
13. Ma H, Diamond SL. Nonviral gene therapy and its delivery systems. Curr Pharm Biotechnol 2001; 2:1-17.
14. Anwer K, Shi M, French MF, Muller SR, Chen W, Liu Q, Proctor BL, Wang J, Mumper R, Singhal A, Rolland A, Alila HW. Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle-specific gene medicine. Hum Gene Ther 1998; 9:659-670.
15. Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther 2000; 2:302-317.
16. Bloomfield VA. Condensation of DNA by multivalent cations: considerations on mechanism. Biopolymers 1991; 31:1471-1481.
17. Bloomfield VA. DNA condensation. Curr Opin Struct Biol 1996; 6:334-41.
18. Adami RC, Collard WT, Gupta SA, Kwok KY, Bonadio J, Rice KJ. Stability of peptide-condensed plasmid DNA formulations. J Pharm Sci 1998; 87:678-683.
19. Park SY, Harries D, Gelbart, WM. Topological defects and the optimum size of DNA condensates. Biophys J 1998; 75:714-720.
20. Wolfert MA, Seymour LW. Atomic force microscopic analysis of the influence of the molecular weight of poly(L)lysine on the size of polyelectrolyte complexes formed with DNA. Gene Ther 1996; 3:269-273.
21. Mumper RJ. Novel polymeric condensing carriers for gene delivery. Proc Intern Symp Control Rel Bioact Mater 1995; 22:178-179.
22. Wagner E, Cotton M, Foisner R, Birnstiel ML. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. Proc Natl Acad Sci USA 1991; 88:4255-4259.
23. Wolfert MA. Characterization of vectors for gene therapy formed by self-assembly of DNA with synthetic block co-polymers. Hum Gene Ther 1996; 7:2123-2133.
24. De Smedt SC, Demeester J, Hennink WE. Cationic polymer based gene delivery systems. Pharm Res 2000; 17:113-126.
25. Ogris M, Steinlein P, Kursa M, Mechtler K, Kircheis R, Wagner E. The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. Gene Ther 1998; 5:1425-1433.
26. Pouton CW, Lucas P, Thomas BJ, Uduehi AN, Milroy DA, Moss SH. Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J Control Release 1998; 53:289-299.
27. Tang MX, Szoka FC. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther 1997; 4: 823-832.
28. Haensler J, Szoka FC. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993; 4:372-379.
29. Bielinska AU, Kukowska-Latallo JF, Baker JR. The interaction of plasmid DNA with polyamidoamine dendrimers: mechanism of complex formation and analysis of alterations induced in nuclease sensitivity and transcriptional activity of the complexed DNA. Biochim Biophys Acta 1997; 1353:180-190.
30. Kabanov VA, Kabanov AV. Interpolyelectrolyte and block ionomer complexes for gene delivery: physicochemical aspects. Adv Drug Deliv Rev 1998; 30:49-60.
31. Izumrudov VA, Zhiryakova MV, Kargov SI, Zezin AB, Kabanov VA. Competitive reactions in solutions of DNA-containing polyelectrolyte complexes. Macromol Symp 1996; 106:179-192.
32. Smith LC, Duguid J, Wadhwa MS, Logan MJ, Tung CH, Edwards V, Sparrow JT. Synthetic peptide-based DNA complexes for nonviral gene delivery. Adv Drug Deliv Rev 1998; 30:115-131.
33. Ruponen M, Yla-Herttuala S, Urtti A. Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies. Biochim Biophys Acta 1999; 1415:331-341.
34. Ferdous A, Watanabe H, Akaike T, Maruyama A. Comb-type copolymer: stabilization of triplex DNA and possible application in antigene strategy. J Pharm Sci 1998; 87: 1400-1405.
35. Perales JC, Ferkol T, Beegen H, Retnoff OD, Hanson RW. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 1994; 91:4086-4090.
36. Garnett MC. Gene-delivery systems using cationic polymers. Crit Rev Ther Drug Carrier Syst 1999; 16:147-207.
37. Behr JP. Gene transfer with synthetic cationic amphiphiles:prospects for gene therapy. Bioconjug Chem 1994; 5:382-389.
38. Godbey WT, Wu KK, Mikos AG. Size matters: molecular weight affects the efficacy of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res 1999; 45: 268-275.
39. Kunath K, von Harpe A, Fisher D, Peterson H, Bickel U, Voigt K, Kissel T. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J Control Release 2003; 89:113-125.
40. Abdallah B, Hassan A, Benoist C, Goula D, Behr JP, Mazabraud A. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther 1996; 7:1947-1954.
41. Boletta A, Benigni A, Lutz J, Remuzzi G, Soria MR, Monaco L. Nonviral gene delivery to the rat kidney with polyethylenimine. Hum Gene Ther 1997; 8:1243-1251.
42. Wightman L, Kircheis R, Rossler V, Carotta S, Ruzicka R, Kursa M, Wagner E. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J Gene Med 2001; 3:362-372.
43. Gharwan H, Wightman L, Kercheis R, Wagner R, Zatloukal K. Nonviral gene transfer into fetal mouse livers (a comparison between the cationic polymer PEI and naked DNA). Gene Ther 2003; 10:810-817.
44. Furgeson D, Kim SW. Linear PEI-cholesterol conjugates for the LDL-R pathway. Mol Ther 2003; 7:S372.
45. Chollet P, Favrot MC, Hurbin A, Coll JL. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002; 4:84-91.
46. Cloninger MJ. Biological applications of dendrimers. Curr Opin Chem Biol 2002; 6: 742-748.
47. Luo D, Haverstick K, Belcheva N, Han E, Saltzman WM. Poly(ethylene glycol)-conjugated PAMAM dendrimer for biocompatible, high-efficiency DNA delivery. Macromolecules 2002; 35:3456-3462.
48. Arima H, Kihara F, Hirayama F, Uekama K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins. Bioconjug Chem 2001; 12:476-484.
49. Maksimenko AV, Gottikh MB, Bertrand JR, Majoral JP, Malvy C. Optimisation of dendrimer-mediated gene transfer by anionic oligomers. J Gene Med 2003; 5: 61-71.
50. MacLaughlin FC, Mumper RJ, Wang J, Tagliaferri JM, Gill I, Hinchcliffe M, Rolland AP. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release 1998; 56:259-272.
51. Maclaughlin FC, Rolland AP. Polymeric systems for gene delivery, chitosan and PINC systems for gene delivery. In: Mathiowitz E, editor. Encyclopedia of controlled drug delivery. New York: Wiley, 1999.
52. Mao HQ, Troung-Le VI, Janes KA, Lin KY, Wang Y, August JT, Leong KW. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 2001; 70:399-421.
53. Chew JL, Wolfowicz CB, Mao HQ, Chua KY. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine 2003; 21:2720-2729.
54. Koping-Hoggard M, Tubulekas I, Guan H, Edwards K, Nilsson M, Varum KM, Artursson P. Chitosan as a nonviral gene delivery system. Structure-property relationships and charateristics compared with polyethylenemine in vitro and after lung administration in vivo. Gene Ther 2001; 8:1108-1121.
55. Patel VR. Preparation and characterization of freeze-dried chitosan-poly(ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach. Pharm Res 1996; 13:588-593.
56. Huang YC, Chiang CH, Yeh MK. Optimizing formulation factors in preparing chitosan microparticles by spray-drying method. J Micro Encapsul 2002; 20:247-252.
57. Kim YH, Gihm SH, Park CR, Lee KY, Kim TW, Kwon IC, Chung H, Jeong SY. Structural characteristics of size-controlled self-aggregates of deoxycholic acid-modified chitosan and their application as a DNA delivery carrier. Bioconjug Chem 2001; 12:932-938.
58. Muzzarelli R, Dumitriu S. Polymeric Biomaterials. New York: Dekker, 1994.
59. Cherng JY, van der Wetering P, Talsma H, Crommelin DJ, Hennink WE. Effect of size and serum proteins on transfection efficiency of poly ((2-dimethylamino)ethyl methacrylate)-plasmid nanoparticles. Pharm Res 1996; 13:1038-1042.
60. Cherng JY, Talsma H, Verrijk R, Crommelin DJ, Hennink WE. The effect of formulation parameters on the size of poly-((2-dimethylamino)ethyl methacrylate)-plasmid complexes. Eur J Pharm Biopharm 1999; 47:215-224.
61. van der Wetering P, Cherng JY, Talsma H, Crommelin DJ, Hennink WE. 2-(Dimethylamino)ethyl methacrylate based (co)polymers as gene transfer agents. J Control Release 1998; 53:145-153.
62. van der Wetering P, Schuurmans-Nieuwenbroek NM, Hennink WE. Comparative transfection studies of human ovarian carcinoma cells in vitro, ex vivo, and in vivo with poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. J Gene Med 1999; 1: 156-165.
63. Zuidman NJ, Posthuma G, Vries ET, Crommelin DJ, Hennink WE, Storm G. Effect of physicochemical characteristics of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes on cellular association and internalization. J Drug Target 2000; 8: 51-66.
64. Wolfert MA, Schacht EH, Toncheva V, Ulbrich K, Nazarova O, Seymou LW. Characterization of vectors for gene therapy formed by self-assembly of DNA with synthetic block copolymers. Hum Gene Ther 1996; 7:2123-2133.
65. Mastrobattista E, Kapel RH, Eggenhuisen MH, Roholl PJ, Crommelin DJ, Hennink WE, Storm G. Lipid-coated polyplexes for targeted gene delivery to ovarian carcinoma cells. Cancer Gene Ther 2001; 8:405-413.
66. Harris JM. PEG: Chemistry and Biological Applications. Washington, DC: American Chemical Society, 1997.
67. Kwok KY, Mckenzie DL, Evers DI, Rice KJ. Formulation of highly soluble poly(ethylene glycol)-peptide DNA condensates. J Pharm Sci 1999; 88:996-1003.
68. Lim DW, Yeom YI, Park TG. Poly(DMAEMA-NVP)-b-PEG-galactose as gene delivery vector for hepatocytes. Bioconjug Chem 2000; 11:688-695.
69. Kakizawa Y, Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 2002; 54:203-222.
70. Choi YH, Liu F, Kim JS, Choi YK, Park JS, Kim SW. Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier. J Control Release 1998; 54:39-48.
71. Katayose S, Kataoka K. Remarkable increase in nuclease resistance of plasmid DNA through supramolecular assembly with poly(ethylene glycol)-poly(L-lysine) block copolymer. J Pharm Sci 1998; 87:160-163.
72. Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. PE Gylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 1999; 6:595-605.
73. Oupicky D, Howard KA, Konak C, Dash PR, Ulbrich K, Seymour LW. Steric stabilization of poly-L-Lysine/DNA complexes by the covalent attachment of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. Bioconjug Chem. 2000; 11:492-501.
74. Ahn CH, Chae SY, Bae YH, Kim SW. Biodegradable poly(ethylenimine) for plasmid DNA delivery. J Control Release 2002; 80:273-282.
75. Petersen H, Merdan T, Kunath K, Fischer D, Kissel T. Poly(ethylenimine-co-L-lactamide-co-succinamide): a biodegradable polyethylenimine derivative with an advantageous pH-dependent hydrolytic degradation for gene delivery. Bioconjug Chem 2002; 13:812-821.
76. Putnam D. Poly(4-hydroxy-L-proline ester): low-temperature polycondensation. Macromolecules 1999; 32:3658-3662.
77. Lim YB. A self-destroying polycationic polymer: biodegradable poly(4-hydroxy-L-proline ester). J Am Chem Soc 1999; 121:5633-5639.
78. Lim YB, Han SO, Kong HU, Lee Y, Park JS, Jeong B, Kim SW. Biodegradable polyester, poly[alpha-(4-aminobutyl)-L-glycolic acid], as a non-toxic gene carrier. Pharm Res 2000; 17:811-816.
79. Zhao Z, Wang J, Mao HQ, Leong KW. Polyphosphoesters in drug and gene delivery. Ad Drug Deliv Rev 2003; 55:483-499.
80. Han S, Mahato, RY, Kim SW. Water-soluble lipopolymer for gene delivery. Bioconjug Chem 2001; 12:337-345.
81. Furgeson DY, Chan WS, Yockman JW, Kim SW. Modified linear polyethylenimine-cholesterol conjugates for DNA complexation. Bioconjugate Chem 2003; 14: 840-847.
82. Furgeson DY, Cohen RN, Mahato RI, Kim SW. Novel water insoluble lipoparticulates for gene delivery. Pharm Res 2002; 19:382-390.
83. Cho YW, Kim JD, Park K. Polycation gene delivery systems: escape from endosomes to cytosol. J Pharm Pharmacol 2003; 55:721-734.
84. Wagner E, Plank C, Zatloukal K, Cotton M, Birnstiel ML. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes:toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci USA 1992; 89:7934-7938.
85. Diebold SS, Plank C, Cotton M, Wagner E, Zenke M. Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat Cell Mol Genet 2002; 27:65-74.
86. Cheung CY, Murthy N. A pH-sensitive polymer that enhances cationic lipid-mediated gene transfer. Bioconjug Chem 2001; 12:906-910.
87. Richardson SC, Man YK, Ferruti P, Duncan R. Poly(amidoamine)s as potential nonviral vectors: ability to form interpolyelectrolyte complexes and to mediate transfection in vitro. Biomacromolecules 2002; 2:1023-1028.
88. Kyriakides TR, Cheung CY, Murthy N, Bornstein P, Stayton PS, Hoffman S. pH-sensitive polymers that enhance intracellular drug delivery in vivo. J Control Release 2002; 78:295-303.
89. Jones RA, Cheung CY, Black FE, Zia JK, Stayton PS, Hoffman AS, Wilson MR. Poly(2-aklacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles. Biochem J 2003; 372:65-75.
90. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Bioinspired pH-responsive polymers for the intracellular delivery of biomolecular drugs. Bioconjug Chem 2003; 14:412-419.
91. Jeong JH, Kim SW, Park TJ. Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug Chem 2003; 14:473-479.
92. Benns JM, Choi JS, Mahato RI, Park JS, Kim SW. pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer. Bioconjug Chem 2000; 11:637-645.
93. Bikram M, Ahne CH, Chae SY, Lee M, Yockman J, Kim SW. Novel biodegradable PEG-PLL-g-His multiblock copolymers for non-viral carrier mediated gene therapy. Mol Ther 2003; 7:S221.
94. Chan CK, Jans DA. Enhancement of polylysine-mediated transferrinfection by nuclear localization sequences: polylysine does not function as a nuclear localization sequence. Hum Gene Ther 1999; 10:1695-702.
95. van Dijk-Wolthuis WN, van de Wetering P, Hinrichs WL, Hofmeyer LJ, Liskamp RM, Crommelin DJ, Hennink WE. A versatile method for the conjugation of proteins and peptides to poly[2-(dimethylamino)ethyl methacrylate]. Bioconjug Chem 1999; 10:687-692.
96. Jensen KD, Nori A, Tijerina M, Kopeckova P, Kopecek J. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J Control Release 2003; 87:89-105.
97. Cartier R, Reszka R. Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems. Gene Ther 2002; 9:157-167.
98. Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988; 263:14621-14624.
99. Wu GY, Wilson JM, Shalaby F, Grossman M, Shafritz DA, Wu CH. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J Biol Chem 1991; 266:14338-14342.
100. Wilson JM, Grossman M, Wu CH, Chowdhury NR, Wu GY, Chowdhury JR. Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. J Biol Chem 1992; 267:963-967.
101. Choi YH, Liu F, Park JS, Kim SW. Lactose-poly(ethylene glycol)-grafted poly-L-lysine as hepatoma cell-targeted gene carrier. Bioconjug Chem 1998; 9:708-718.
102. Choi YH, Liu F, Choi JS, Kim SW, Park JS. Characterization of a targeted gene carrier, lactose-polyethylene glycol-grafted poly-L-lysine and its complex with plasmid DNA. Hum Gene Ther 1999; 10:2657-2665.
103. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73:2432-2443.
104. Hofland HE, Masson C, Iginnla S, Osetinsky I, Reddy JA, Lemon CP, Scherman D, Bessodes M, Wils P. Folate-targeted gene transfer in vivo. Mol Ther 2002; 5: 739-744.
105. Benns JM, Maheshwari A, Furgesen DY, Mahato RI, Kim SW. Folate-PEG-folate-graft-polyethylenimine-based gene delivery. J Drug Target 2001; 9:123-139.
106. Benns JM, Mahato RI, Kim SW. Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. J Control Release 2002; 79: 255-269.
107. Ward CM, Pechar M, Oupicky D, Ulbrich K, Seymour LW. Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo. J Gene Med 2002; 4:536-547.
108. van Steenis JH, van Maarseveen EM, Verbaan FJ, Verrijk R, Crommelin DJA, Storm G, Hennink WE. Preparation and characterization of folate-targeted PEG-coated PDMAEMA-based polyplexes. J Control Release 2003; 87:167-176.
109. Taxman DJ, Lee ES, Wojchowski DM. Receptor-targeted transfection using stable maleimido-transferrin/thio-poly-L-lysine conjugates. Anal Biochem 1993; 213: 97-103.
110. Kircheis R, Kichler A, Wallner G, Kursa G, Ogris M, Heider KH, Zauner W, Wagner E. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery Gene Ther 1997; 4:409-418.
111. Kircheis R, Wightman L, Schreiber A, Robitza B, Rossler V, Kursa M, Wagner E. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther 2001; 8:28-40.
112. Kabanov AV, Kabanov VA. DNA complexes with polycations for the delivery of genetic material into cells. Bioconjug Chem 1995; 6:7-20.
113. Hildebrandt IJ, Iyer M, Wagner E, Gambhir SS. Optical imaging of transferrin targeted PEI/DNA complexes in living subjects. Gene Ther 2003; 10:758-764.
114. Kim JS. A new non-viral DNA delivery vector: the terplex system. J Control Release 1998; 53:175-182.
115. Yu L, Nielson M, Han SO, Kim SW. Terplex DNA gene carrier system targeting artery wall cells. J Control Release 2001; 72:179-189.
116. Suh W, Chung JK, Park SH, Kim SW. Anti-JL1 antibody-conjugated poly (L-lysine) for targeted gene delivery to leukemia T cells. J Control Release 2001; 72:171-178.
117. Suzuki M, Takayanagi A, Shimizu N. Recombinant single-chain antibodies with various oligopeptide tails for targeted gene delivery. Gene Ther 2003; 10:781-788.
118. Suh W, Han SO, Yu L, Kim SW. An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol Ther 2002; 6:664-672.
119. Rolland AP, Mumper RJ. Plasmid delivery to muscle: recent advances in polymer delivery systems. Ad Drug Deliv Rev 1998; 30:151-172.
120. Mumper RJ. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle. Pharm Res 1996; 13:701-709.
121. Mumper RJ, Wang J, Klakamp SL, Nitta H, Anwer K, Tagliaferri F, Rolland AP. Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle. J Control Release 1998; 52:191-203.
122. Alila H, Coleman M, Nitta H, French M, Anwer K, Liu Q, Meyer T, Wang J, Mumper RJ, Singhal A, Rolland AP, Alila HW. Expression of biologically active human insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats. Hum Gene Ther 1997; 8:1785-1795.
123. Simons M, Edelman ER, Dekeyser DL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359:67-70.
124. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1995; 1:541-545.
125. Lemieux P, Guerin N, Paradis G, Proulx R, Chistyakova L, Kabanov A, Alakhov V. A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle. Gene Ther 2000; 7:986-991.
126. Feldman LJ, Pastore CJ, Aubailly N, Kearney M, Chen D, Perricaudet M, Steg PG, Isner JM. Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors. Gene Ther 1997; 4:189-198.
127. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002; 82:189-212.
128. Fewell JG, Madaughlin F, Mehta V, Gondo M, Nicol F, Wilson E, Smith LC. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol Ther 3 (2001) 574-583.
129. Nicol F, Wong M. Poly-L-glutamate, an anionic polymer, enhances transgene expression for plasmids delivered by intramuscular injection with in vivo electroporation. Gene Ther 2002; 9:1351-1358.
130. Bonadio J. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med 1999; 5:753-759.
131. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, Oh H, Rhee BG, Mestecky J, Moldovanu Z, Morgan M, Weitman S. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001; 72:203-215.
132. Li, Z, Ning W, Wang J, Choi A, Lee PY, Tyagi P, Huang L. Controlled gene delivery system based on thermosensitive biodegradable hydrogel. Pharm Res 2002; 20: 884-888.
133. Kushibiki T, Tomoshige R, Fukunaka Y, Kakemi M, Tabata Y. In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents. J Control Release 2003; 90:207-216.
134. Wang J, Zhang PC, Mao HQ, Leong KW. Enhanced gene expression in mouse muscle by sustained release of plasmid DNA using PPE-EA as a carrier. Gene Ther 2002; 9: 1254-1261.
135. Megeed Z, Cappello J, Ghandehari H. Controlled release of plasmid DNA from a genetically engineered silk-elastinlike hydrogel. Pharm Res 2002; 19:954-959.
136. Meilander NJ, Pasumarthy MK, Kowalczyk TH, Cooper MJ, Bellamkonda RV. Sustained release of plasmid DNA using lipid microtubules and agarose hydrogel. J Control Release 2003; 88:321-331.
137. Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, Biron CA. Mechanism of interleukin 12-mediated toxicities during experimental viral infections:role of tumor necrosis factor and glucocorticoids. J Exp Med 1995; 181: 901-914.
138. Marshall E. Cancer trial of interleukin-12 halted. Science 1995; 268:1555-1557.
139. Coleman M. Nonviral interferon alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response. Hum Gene Ther 1998; 9:2223-2230.
140. Mahato RI, Lee M, Han S, Maheshwari A, Kim SW. Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol Ther 2001; 4:130-138.
141. Mendiratta SK, Quezada A, Matar M, Tull NM, Bishop JS, Nordstrom JL, Pericle F. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma. Hum Gene Ther 2000; 11: 1851-1862.
142. Mendiratta SK, Quezada A, Matar M, Tull NM, Bishop JS, Nordstrom JL, Pericle F. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Gene Ther 1999; 6: 833-839.
143. Li D, Shugert E, Guo M, Bishop JS, O'Malley BM. Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001; 127:1319-1324.
144. Li D, Zeiders JW, Liu S, Guo M, Xu Y, Bishop JS, O'Malley BW. Combination nonviral cytokine gene therapy for head and neck cancer. Laryngoscope 2001; 111: 815-820.
145. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-483.
146. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393:474-478.
147. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-480.
148. Coll JL, Chollet P, Brambilla E, Desplanques D, Behr JP, Favrot M. In vivo delivery to tumors of DNA complexed with linear polyethylenimine. Hum Gene Ther 1999; 10:1659-1666.
149. Nakanishi H, Satoh E, Asada H, Morioka H, Kishida T, Nakao M, Mizutani M, Kita M, Imanishi J, Miki T. Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo. Gene Ther 2003; 10:434-442.
150. Maruyama-Tabata H, Harada Y, Matsumura T, Satoh E, Cui F, Iwai M, Kita M, Hibi S, Imanishi J, Sawada T, Mazada O. Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer. Gene Ther 2000; 7: 53-60.
151. Yockman JW, Maheshwari A, Hans S, Kim SW. Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMV-IL-12 complexes. J. Control Rel 2003; 87:177-186.
152. Maheshwari A, Hans S, Mahato RI, Kim SW. Biodegradable polymer-based IL-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in antitumor activity. Gene Ther 2002; 9:1075-1084.
153. Gautam A, Densmore CL. Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol Ther 2000; 2:63-70.
154. Gautam A, Densmore CL, Waldrep JC. Pulmonary cytokine responses associated with PEI-DNA aerosol gene therapy. Gene Ther 2001; 8:254-257.
155. Gautam A, Densmore, CL, Waldrep JL. Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes. Mol Ther 2000; 2:318-323.
156. Gautam A, Densmore CL. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002; 9: 28-36.
157. Densmore CL, Kleinerman ES, Gautam A, Jia SF, Knight V. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther 2001; 8:619-627.
158. Jia SF, Worth LL, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther 2002; 9:260-266.
159. Gautam A, Waldrep JC, Densmore CL, Knight V. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Ther 2002; 9:353-357.
160. Densmore CL, Orson FM, Xu B, Knight V. Aerosol delivery of robust polyethylenei-mine-DNA complexes for gene therapy and genetic immunization. Mol Ther 2000; 1:180-188.
161. Densmore CL, Giddings TH, Waldrep TC, Kinsey BM, Knight V. Gene transfer by guanidinium-cholesterol:dioleoylphosphatidyl-ethanolamine liposome-DNA complexes in aerosol. J Gene Med 1999; 1:251-264.
162. Ernst N, Ulrichskotter S, Rosenecker J. Interaction of liposomal and polycationic transfection complexes with pulmonary surfactant. J Gene Med 1999; 1:331-340.
163. Ruley HE. p53 and response to chemotherapy and radiotherapy. Important Adv Oncol 1996;37-56.
164. Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 1996; 40:197-223.
165. Aoki K, Furuhata S, Hatanaka K, Yoshida T. Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity. Gene Ther 2001; 8:508-514.
166. Plank C, Mechter K, Szoka FC, Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum. Gene Ther 1996; 7:1437-1446.
167. Kircheis R, Schuller S, Brunner S, Ogris M, Wagner E. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J Gene Med 1999; 1:111-120.
168. Kircheis R, Blessing T, Brunner S, Wagner E. Tumor targeting with surface-shielded ligand-polycation DNA complexes. J Control Release 2001; 72:165-170.
169. Kircheis R, Ostermann E, Wagner E. Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther 2002; 9:673-680.
170. Kircheis R, Wightman L, Wagner E. Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. Gene Ther 2002; 9:731-735.
171. Wolschek MF, Thallinger C, Wagner E, Jansen B. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology 2002; 36:1106-1114.
172. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in non-human cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19: 32S-40S.
173. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 2003; 10:285-291.
174. Morishita R. Recent progress in gene therapy for cardiovascular disease. Circ J 2002; 66:1077-1086.
175. Nakamura T, Morishita R, Ogiraha T. Molecular strategy using cis-element "decoy" of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 2002; 9:488-494.
176. Klugherz BD, Jones PL, Chen W, Levy RJ. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 2000; 18:1181-1184.
177. Young SW, Litt M, Karlsberg R, Snell J, Schaer GL. Safety profile of VLTS-589 angiogenesis agent during the first use in humans with peripheral arterial disease. Molecular Therapy 2003; 7:S240.
178. Kasahara H, Tanaka E, Ando K, Mori H. Biodegradable gelatin hydrogel potentiates the angiogenic effect of fibroblast growth factor 4 plasmid in rabbit hindlimb ischemia. J Am. Coll Cardiol 2003; 41:1056-1062.
179. Turunen MP, Hiltunen MO, Yla-Herttuala S. Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer-plasmid complexes. Gene Ther 2001; 6:6-11.
180. Qin L, Pahud DR, Ding YL, Bromberg JS. Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine dendrimers. Human Gene Ther 1998; 9: 553-560.
181. Lee M, Rentz J, Han SO, Bull DA, Kim SW. Water-soluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther 2003; 10:585-593.
182. Lee M, Rentz J, Bikram M, Han S, Bull DA, Kim SW. Hypoxia inducible VEGF gene delivery to ischemic myocardium using water soluble lipopolymers. Gene Ther 2003; 10:1535-1542.
183. Nah JW, Yu L, Han SO, Ahn CH, Kim SW. Artery wall binding peptide-poly(ethylene glycol)-grafted-poly(L-lysine)-based gene delivery to artery wall cells. J Control Release 2002; 78:273-284.
184. Affleck DC, Yu L, Bull DA, Bailey SH, Kim SW. Augmentation of myocardial transfection using Terplex DNA: a non-viral gene delivery system. Gene Ther 2001; 8:349-353.
185. Shi Y, Fard A, Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994; 90:944-51.
186. Morishita R. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90:8474-8478.
187. Xu R. Diabetes gene therapy: potential and challenges. Curr Gene Ther 2003; 3: 65-82.
188. Yamaoka T. Gene therapy for diabetes mellitus. Curr Mol Med 2001; 1:325-337.
189. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18:430-441.
190. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 1998; 435:583-594.
191. Nauck MA, Heimesaat MM, Orskov C, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91:301-307.
192. Nauck MA. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998; 21:1925-1931.
193. Rachman J, Barrow BA, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40:205-211.
194. Oh S, Lee M, Ko KS, Choi S, Kim SW. GLP-1 gene delivery for the treatment of type 2 diabetes. Mol Ther 2003; 7:478-483.
195. Menard V, Jacobs H, Jun HS, Yoon JW, Kim SW. Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice. Pharm Res 1999; 16:1059-1066.
196. Rapoport MJ, Jaramillo A, Delovitch TL. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178:87-99.
197. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71:169-175.
198. Zheng XX, Steele AW, Strom TB. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 1997; 158:4507-4513.
199. Goudy K. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA 2001; 98:13913-13918.
200. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158:97-129.
201. Rabinowitz JE, Samulski J. Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol 1998; 9:470-475.
202. Koh JJ, Ko KS, Lee M, Han S, Park JS, Kim SW. Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice. Gene Ther 2000; 7:2099-2104.
203. Ko KS, Lee M, Koh JJ, Kim SW. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol Ther 2001; 4:313-316.
204. Jun HS, Khil LY, Yoon JW. Role of glutamic acid decarboxylase in the pathogenesis of type I diabetes. Cell Mol Life Sci 2002; 59:1892-1901.
205. Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 1999; 284:1183-1187.
206. Lee, M, Han SO, Ko KS, Koh JJ, Park, JS, Yoon JW, Kim SW. Repression of GAD autoantigen expression in pancreatic beta cells by delivery of antisense plasmid/PEG-g-PLL complex. Mol Ther 2001; 4:339-346.
207. Martinenghi S, Biressi S, Amadio S, Falqui L. Human insulin production and amelioration of diabetes in mice by electrotransfer-enhanced plasmid DNA gene transfer to the skeletal muscle. Gene Ther 2002; 9:1429-1437.
208. Alam T, Sollinger HW. Glucose-regulated insulin production in hepatocytes. Transplantation 2002; 74:1781-1787.
209. Contreras JL, Bilbao G, Thomas JM. Cytoprotection of pancreatic islets before and soon after transplantation by gene transfer of the anti-apoptotic Bcl-2 gene. Transplantation 2001; 71:1015-1023.
210. Duvillie B. Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to beta-cell hyperplasia in mutant mice lacking insulin. Endocrinology 2002; 143:1530-1537.
211. Giannoukakis N, Thomson A, Robbins P. Gene therapy in transplantation. Gene Ther 1999; 6:499-511.
212. Gorden DL. Vascular endothelial growth factor is increased in devascularized rat islets of Langerhans in vitro. Transplantation 1997; 63:436-443.
213. Mahato RI, Henry J, Narang AS, Sabek S, Fraga D, Kotb M, Gabor O. Cationic lipid and polymer-based gene delivery to human pancreatic islet cells. Mol Ther 2003; 7: 89-100.
214. Mendiratta SK, Thai G, Pericle F. Therapeutic tumor immunity induced by poly-immunization with melanoma antigens gp100 and TRP-2. Cancer Res 2001; 61: 859-863.
215. Mir LM. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96:4262-4267.
216. Neumann E, Kakorin S, Toensing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg 1999; 48:3-16.
217. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998; 15: 1326-1331.
218. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 2001; 14:201-207.
219. van der Lubben IM. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 2001; 22:687-694.
220. Illum L, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51:81-96.
221. Mohapatra SS. Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus. Pediatr Infect Dis J 2003; 22:S103-S104.
222. Kumar M, Behera AK, Chen LC, Mohapatra SS. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002; 13:1415-1425.
223. Iqbal M, Lin W, Davis SS, Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 2003; 21:1478-1485.
224. Roy K, Mao HQ, Hunag SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1000; 5:387-391.
225. Orson FM, Kinsey BM, Hua PJ, Bhogal BS, Densmore CL, Barry MA. Genetic immunization with lung-targeting macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic and mucosal immune responses. J Immunol 2000; 164:6313-6321.